Dyne Therapeutics
232 hedge funds and large institutions have $3.48B invested in Dyne Therapeutics in 2025 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 95 increasing their positions, 58 reducing their positions, and 29 closing their positions.
103% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 29
76% more capital invested
Capital invested by funds: $1.97B → $3.48B (+$1.51B)
64% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 58
15.03% more ownership
Funds ownership: 109.54% → 124.57% (+15%)
12% more funds holding
Funds holding: 207 → 232 (+25)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
38% less call options, than puts
Call options by funds: $5.14M | Put options by funds: $8.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$279M |
| 2 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$90.9M |
| 3 |
PA
Perceptive Advisors
New York
|
+$55.6M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$30.6M |
| 5 |
BlackRock
New York
|
+$29.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$50.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$44.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$42.5M |
| 4 |
RI
RTW Investments
New York
|
-$36.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$26.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CLOS
251
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| – | -$228K | -18,000 | Closed |
|
|
QT
252
Quantbot Technologies
New York
| – | -$222K | -17,513 | Closed |
|
253
Prudential Financial
Newark,
New Jersey
| – | -$167K | -13,210 | Closed |
|
|
OC
254
Oppenheimer & Co
New York
| – | -$144K | -11,364 | Closed |
|
|
AWA
255
Arkadios Wealth Advisors
Atlanta,
Georgia
| – | -$128K | -10,104 | Closed |
|
|
EP
256
Eversept Partners
New York
| – | -$127K | -10,000 | Closed |
|
|
QL
257
Quarry LP
New York
| – | -$91.7K | -7,250 | Closed |
|
|
GWSG
258
GPS Wealth Strategies Group
Centennial,
Colorado
| – | -$5.06K | -400 | Closed |
|
|
WTA
259
Washington Trust Advisors
Wellesley,
Massachusetts
| – | -$1.58K | -125 | Closed |
|
|
CA
260
Clearstead Advisors
Cleveland,
Ohio
| – | -$469 | -37 | Closed |
|
|
ASN
261
Advisory Services Network
Atlanta,
Georgia
| – | -$177 | -14 | Closed |
|
DYN Hedge Fund Activity: Q4 2025 in Review
232 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q4 2025, worth a combined $3.48B — up 76% from $1.97B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new DYN positions and 29 closed out — a net gain of 30 holders — while 95 added to existing stakes and 58 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $279M. The largest seller was Vestal Point Capital, cutting an estimated $50.3M.
- 232 institutional investors held Dyne Therapeutics (DYN) as of Q4 2025, up from 207 in Q3 2025.
- Funds reported $3.48B of Dyne Therapeutics stock for Q4 2025, up 76% quarter-over-quarter.
- 59 funds opened new Dyne Therapeutics positions in Q4 2025 and 29 closed out, a net change of +30 holders.
- The largest Dyne Therapeutics buyer in Q4 2025 was T. Rowe Price Investment Management, an estimated $279M added.
- The largest Dyne Therapeutics seller in Q4 2025 was Vestal Point Capital, an estimated $50.3M sold.
Based on aggregated 13F filings for Q4 2025.